265. 脂肪萎縮症 Lipodystrophy Clinical trials / Disease details

臨床試験数 : 116 / 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97

16 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05088460 (ClinicalTrials.gov)	January 24, 2022	12/10/2021	A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)	A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients With Familial Partial Lipodystrophy	Familial Partial Lipodystrophy;Metabolic Abnormalities	Drug: REGN4461;Drug: Matching Placebo	Regeneron Pharmaceuticals	NULL	Not yet recruiting	18 Years	N/A	All	40	Phase 2	NULL
2	NCT04159415 (ClinicalTrials.gov)	January 7, 2020	7/11/2019	Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy	A Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy	Generalized Lipodystrophy	Drug: Placebo;Drug: Low-Dose REGN4461;Drug: High-dose REGN4461	Regeneron Pharmaceuticals	NULL	Active, not recruiting	12 Years	N/A	All	16	Phase 2	United States;Peru;Russian Federation;Turkey
3	EUCTR2017-003014-22-AT (EUCTR)	25/06/2018	29/05/2018	Leptin in hepatic lipid metabolism in humans	The role of leptin in regulating hepatic lipid metabolism in humans - Leptin and hepatic lipid metabolism	lipodystrophy patients, patients after liver transplantation and healthy controls;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Trade Name: Myalept Product Name: Myalept INN or Proposed INN: metrelpetin Other descriptive name: METRELEPTIN	Medical University of Vienna	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	43	Phase 2	Austria
4	NCT03262610 (ClinicalTrials.gov)	February 17, 2017	22/8/2017	Setemelanotide in a Single Patient With Partial Lipodystrophy	Expanded-access for the Use of Setemelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune Diseases	Hypertriglyceridemia	Drug: Setmelanotide	Rhythm Pharmaceuticals, Inc.	NULL	No longer available	15 Years	15 Years	Female			United States
5	NCT02654977 (ClinicalTrials.gov)	September 29, 2015	20/1/2015	CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy	CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METRELEPTIN) in Various Forms of Partial Lipodystrophy	Familial Partial Lipodystrophy;Nonalcoholic Steatohepatitis;NAFLD	Drug: Metreleptin	University of Michigan	NULL	Completed	5 Years	N/A	All	11	Phase 2	United States
6	NCT01778556 (ClinicalTrials.gov)	January 26, 2013	26/1/2013	Short-term Effects of Leptin in People With Lipodystrophy	Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake	Lipodystrophy	Biological: Metreleptin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	14 Years	70 Years	All	25	Phase 2	United States
7	NCT01679197 (ClinicalTrials.gov)	October 8, 2012	31/8/2012	Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy	Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy	Fatty Liver Disease, Nonalcoholic;Nonalcoholic Steatohepatitis;Lipodystrophy	Drug: Metreleptin	University of Michigan	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	5 Years	N/A	All	23	Phase 2	United States
8	JPRN-UMIN000003679	2010/08/01	01/06/2010	Long-term safety clinical trial of leptin-replacement therapy in patients with lipodystrophy after introduction of the treatment		lipodytrophy	subcutaneous injection of human recombinant leptin	Kyoto University Hospital	NULL	Complete: follow-up complete	6years-old	Not applicable	Male and Female	11	Not selected	Japan
9	JPRN-UMIN000002818	2010/08/01	01/01/2010	Phase 2 trial of leptin-replacement therapy for patients with lipodystrophy		lipodystrophy	administration of recombinant methionyl human leptin	Department of Medicine and Clinical Science, Kyoto University Graduate School of MedicineTranslational Research Center, Kyoto University Hospital	NULL	Complete: follow-up complete	6years-old	Not applicable	Male and Female	3	Phase 2	Japan
10	NCT00362440 (ClinicalTrials.gov)	August 2006	9/8/2006	Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome	A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial	HIV Lipodystrophy	Drug: Leptin;Drug: Pioglitazone or metformin;Drug: Placebo	Beth Israel Deaconess Medical Center	American Diabetes Association	Completed	18 Years	N/A	All	9	Phase 2	United States
11	NCT00896298 (ClinicalTrials.gov)	April 2006	8/5/2009	Trial of Leptin Replacement Therapy in Patients With Lipodystrophy	Double-Blind, Placebo-Controlled Trial of Leptin Replacement Therapy in Patients With Lipodystrophy	Hypoleptinemia;Generalized Lipodystrophy;Partial Lipodystrophy;Insulin Resistance	Drug: Leptin;Drug: Placebo	University of Texas Southwestern Medical Center	NULL	Completed	6 Years	70 Years	All	25	Phase 2/Phase 3	United States
12	NCT01511016 (ClinicalTrials.gov)	February 2003	11/1/2012	Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome	The Effect of Leptin Therapy on Abnormal Lipid Kinetics in Subjects With HIV Lipodystrophy Syndrome	HIV Lipodystrophy	Drug: Human recombinant leptin (metreleptin);Drug: Placebo	Baylor College of Medicine	NULL	Completed	18 Years	64 Years	Male	17	N/A	United States
13	NCT00461552 (ClinicalTrials.gov)	January 2003	16/4/2007	Therapeutic Approaches to HAART-Induced Lipodystrophy	Therapeutic Approaches to HAART-Induced Lipodystrophy	HIV Infections;Lipodystrophy	Drug: Leptin;Other: Placebo	University of Texas Southwestern Medical Center	Amylin Pharmaceuticals, LLC.	Completed	14 Years	65 Years	All	23	Phase 2	United States
14	NCT00140244 (ClinicalTrials.gov)	December 2001	30/8/2005	Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome	Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients	HAART-induced Lipodystrophy and Metabolic Syndrome	Drug: r-metHuLeptin;Drug: Placebo	Beth Israel Deaconess Medical Center	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Amgen	Completed	18 Years	N/A	All	7	Phase 2	United States
15	NCT00025883 (ClinicalTrials.gov)	October 2001	27/10/2001	Leptin to Treat Lipodystrophy	Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy	Lipodystrophy	Drug: Metreleptin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	6 Months	N/A	All	103	Phase 2	United States
16	NCT00005905 (ClinicalTrials.gov)	June 2000	9/6/2000	Leptin to Treat Lipodystrophy	Efficacy of Leptin Replacement in Treatment of Lipodystrophy	Lipodystrophy	Drug: hu Leptin (A-100)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	N/A	N/A	Both	20	Phase 2	United States

先頭へ